TAKEDA PHARMACEUTICAL CO LTD - 12 Oct 2021 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Role
10%+ Owner
Signature
/s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited
Issuer symbol
N/A
Transactions as of
12 Oct 2021
Net transactions value
$0
Form type
4
Filing time
15 Oct 2021, 18:40:19 UTC
Previous filing
15 Oct 2021
Next filing
21 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction THRX Common Stock Conversion of derivative security +1,615,427 1,615,427 12 Oct 2021 See explanation F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Series A Preferred Stock Conversion of derivative security $0 -1,615,427 -100% $0.000000* 0 12 Oct 2021 Common Stock 1,615,427 See explanation F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

TAKEDA PHARMACEUTICAL CO LTD is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date.
F2 This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc.
F3 The reportable securities are owned directly by ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of these securities is comprised of the reportable securities owned by ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.